Loading…

The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II

The novel amide linked Angiotensin II potent cyclic analogue, c-[Sar1,Lys3,Glu5] ANG II 19 has been designed and synthesized in an attempt to test the aromatic ring clustering and the charge relay bioactive conformation we have recently suggested for ANG II. This constrained cyclic analogue was synt...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2000, Vol.8 (1), p.1-10
Main Authors: MATSOUKAS, J. M, POLEVAYA, L, ANCANS, J, MAVROMOUSTAKOS, T, KOLOCOURIS, A, ROUMELIOTI, P, VLAHAKOS, D. V, YAMDAGNI, R, QIAO WU, MOORE, G. J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3
cites cdi_FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3
container_end_page 10
container_issue 1
container_start_page 1
container_title Bioorganic & medicinal chemistry
container_volume 8
creator MATSOUKAS, J. M
POLEVAYA, L
ANCANS, J
MAVROMOUSTAKOS, T
KOLOCOURIS, A
ROUMELIOTI, P
VLAHAKOS, D. V
YAMDAGNI, R
QIAO WU
MOORE, G. J
description The novel amide linked Angiotensin II potent cyclic analogue, c-[Sar1,Lys3,Glu5] ANG II 19 has been designed and synthesized in an attempt to test the aromatic ring clustering and the charge relay bioactive conformation we have recently suggested for ANG II. This constrained cyclic analogue was synthesized by connecting the Lys3 amino and Glu5 carboxyl side chain groups, and it was found to be potent in the rat uterus assay and in anesthetized rabbits. The central part of the molecule is fixed covalently in the conformation predicted according to the backbone bend conformational model proposed for Angiotensin II. The obtained results using a combination of 2D NMR, 1D NOE spectroscopy and molecular modeling revealed a similar Tyr4-Ile5-His6 bend, a His6-Pro7 trans configuration and a side chain aromatic ring cluster of the key aminoacids Tyr4, His6, Phe8 for c-[Sar1,Lys3,Glu5] ANG II as it has been found for ANG II (Matsoukas, J. H.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Markriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G. J. J. Biol. Chem. 1994, 269, 5303). Previous study of the conformational properties of the Angiotensin II type I antagonist [Hser(gamma-OMe)8] ANG II (Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos. D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H.; Ganter, R.; Moore, G. J. J. Med. Chem. 1995, 38, 4660) using 1-D NOE spectroscopy coupled with the present study of the same type of lead antagonist Sarilesin revealed that the Tyr4-Ile5-His6 bend, a conformational property found in Angiotensin II is not present in type I antagonists. The obtained results provide an important conformational difference between Angiotensin II agonists and type I antagonists. It appears that our synthetic attempt to further support our proposed model was successful and points out that the charge relay system and aromatic ring cluster are essential stereoelectronic features for Angiotensin II to exert its biological activity.
doi_str_mv 10.1016/S0968-0896(99)00266-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72221427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72221427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3</originalsourceid><addsrcrecordid>eNpdkc1OJCEUhYkZo-3PIzhhMZnoohSKKqpZGuNPJyYu1DWhLtDNpApaqFr0Y_jGQ3V3Zoyry4XvnBvuQeiCkmtKKL95JYLPCzIX_FKIK0JKzovmAM1oxauCMUF_oNk_5BidpPSHZKoS9Agd0-mlrOcz9Pm2Mlib5JYeK69x2vhhlduEg8UKr8Ng_IBv_dJNp-Q8XiwwbKBzkHnVheVoMARvXewTzlIcnV9i6MY0mIijAbMeQtwiIfZqcMFP1hO5yhfBm2_uZ-jQqi6Z8309Re8P9293T8Xzy-Pi7va5AMb4UFBQBoBVrWDEABGa8BZszfS8ppbrqmktq7RW-fegaVPqFqgGzrgWdVNzy07R753vOoaP0aRB9i6B6TrlTRiTbMqypFXZZLDegRBDStFYuY6uV3EjKZFTFnKbhZwWLYWQ2yzkpPu5HzC2vdFfVLvlZ-DXHlAJVGej8uDSfy4zRBD2FzsDlS8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72221427</pqid></control><display><type>article</type><title>The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II</title><source>ScienceDirect Freedom Collection</source><creator>MATSOUKAS, J. M ; POLEVAYA, L ; ANCANS, J ; MAVROMOUSTAKOS, T ; KOLOCOURIS, A ; ROUMELIOTI, P ; VLAHAKOS, D. V ; YAMDAGNI, R ; QIAO WU ; MOORE, G. J</creator><creatorcontrib>MATSOUKAS, J. M ; POLEVAYA, L ; ANCANS, J ; MAVROMOUSTAKOS, T ; KOLOCOURIS, A ; ROUMELIOTI, P ; VLAHAKOS, D. V ; YAMDAGNI, R ; QIAO WU ; MOORE, G. J</creatorcontrib><description>The novel amide linked Angiotensin II potent cyclic analogue, c-[Sar1,Lys3,Glu5] ANG II 19 has been designed and synthesized in an attempt to test the aromatic ring clustering and the charge relay bioactive conformation we have recently suggested for ANG II. This constrained cyclic analogue was synthesized by connecting the Lys3 amino and Glu5 carboxyl side chain groups, and it was found to be potent in the rat uterus assay and in anesthetized rabbits. The central part of the molecule is fixed covalently in the conformation predicted according to the backbone bend conformational model proposed for Angiotensin II. The obtained results using a combination of 2D NMR, 1D NOE spectroscopy and molecular modeling revealed a similar Tyr4-Ile5-His6 bend, a His6-Pro7 trans configuration and a side chain aromatic ring cluster of the key aminoacids Tyr4, His6, Phe8 for c-[Sar1,Lys3,Glu5] ANG II as it has been found for ANG II (Matsoukas, J. H.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Markriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G. J. J. Biol. Chem. 1994, 269, 5303). Previous study of the conformational properties of the Angiotensin II type I antagonist [Hser(gamma-OMe)8] ANG II (Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos. D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H.; Ganter, R.; Moore, G. J. J. Med. Chem. 1995, 38, 4660) using 1-D NOE spectroscopy coupled with the present study of the same type of lead antagonist Sarilesin revealed that the Tyr4-Ile5-His6 bend, a conformational property found in Angiotensin II is not present in type I antagonists. The obtained results provide an important conformational difference between Angiotensin II agonists and type I antagonists. It appears that our synthetic attempt to further support our proposed model was successful and points out that the charge relay system and aromatic ring cluster are essential stereoelectronic features for Angiotensin II to exert its biological activity.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(99)00266-7</identifier><identifier>PMID: 10968258</identifier><language>eng</language><publisher>Oxford: Elsevier Science</publisher><subject>Angiotensin II - chemical synthesis ; Angiotensin II - chemistry ; Angiotensin II - pharmacology ; Animals ; Biological and medical sciences ; Female ; Hormones. Endocrine system ; Medical sciences ; Nuclear Magnetic Resonance, Biomolecular ; Peptides, Cyclic - chemistry ; Peptides, Cyclic - pharmacology ; Pharmacology. Drug treatments ; Protein Conformation ; Rats ; Receptors, Angiotensin - chemistry ; Receptors, Angiotensin - metabolism ; Uterus - drug effects</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2000, Vol.8 (1), p.1-10</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3</citedby><cites>FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1258090$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10968258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MATSOUKAS, J. M</creatorcontrib><creatorcontrib>POLEVAYA, L</creatorcontrib><creatorcontrib>ANCANS, J</creatorcontrib><creatorcontrib>MAVROMOUSTAKOS, T</creatorcontrib><creatorcontrib>KOLOCOURIS, A</creatorcontrib><creatorcontrib>ROUMELIOTI, P</creatorcontrib><creatorcontrib>VLAHAKOS, D. V</creatorcontrib><creatorcontrib>YAMDAGNI, R</creatorcontrib><creatorcontrib>QIAO WU</creatorcontrib><creatorcontrib>MOORE, G. J</creatorcontrib><title>The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>The novel amide linked Angiotensin II potent cyclic analogue, c-[Sar1,Lys3,Glu5] ANG II 19 has been designed and synthesized in an attempt to test the aromatic ring clustering and the charge relay bioactive conformation we have recently suggested for ANG II. This constrained cyclic analogue was synthesized by connecting the Lys3 amino and Glu5 carboxyl side chain groups, and it was found to be potent in the rat uterus assay and in anesthetized rabbits. The central part of the molecule is fixed covalently in the conformation predicted according to the backbone bend conformational model proposed for Angiotensin II. The obtained results using a combination of 2D NMR, 1D NOE spectroscopy and molecular modeling revealed a similar Tyr4-Ile5-His6 bend, a His6-Pro7 trans configuration and a side chain aromatic ring cluster of the key aminoacids Tyr4, His6, Phe8 for c-[Sar1,Lys3,Glu5] ANG II as it has been found for ANG II (Matsoukas, J. H.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Markriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G. J. J. Biol. Chem. 1994, 269, 5303). Previous study of the conformational properties of the Angiotensin II type I antagonist [Hser(gamma-OMe)8] ANG II (Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos. D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H.; Ganter, R.; Moore, G. J. J. Med. Chem. 1995, 38, 4660) using 1-D NOE spectroscopy coupled with the present study of the same type of lead antagonist Sarilesin revealed that the Tyr4-Ile5-His6 bend, a conformational property found in Angiotensin II is not present in type I antagonists. The obtained results provide an important conformational difference between Angiotensin II agonists and type I antagonists. It appears that our synthetic attempt to further support our proposed model was successful and points out that the charge relay system and aromatic ring cluster are essential stereoelectronic features for Angiotensin II to exert its biological activity.</description><subject>Angiotensin II - chemical synthesis</subject><subject>Angiotensin II - chemistry</subject><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Hormones. Endocrine system</subject><subject>Medical sciences</subject><subject>Nuclear Magnetic Resonance, Biomolecular</subject><subject>Peptides, Cyclic - chemistry</subject><subject>Peptides, Cyclic - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Conformation</subject><subject>Rats</subject><subject>Receptors, Angiotensin - chemistry</subject><subject>Receptors, Angiotensin - metabolism</subject><subject>Uterus - drug effects</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpdkc1OJCEUhYkZo-3PIzhhMZnoohSKKqpZGuNPJyYu1DWhLtDNpApaqFr0Y_jGQ3V3Zoyry4XvnBvuQeiCkmtKKL95JYLPCzIX_FKIK0JKzovmAM1oxauCMUF_oNk_5BidpPSHZKoS9Agd0-mlrOcz9Pm2Mlib5JYeK69x2vhhlduEg8UKr8Ng_IBv_dJNp-Q8XiwwbKBzkHnVheVoMARvXewTzlIcnV9i6MY0mIijAbMeQtwiIfZqcMFP1hO5yhfBm2_uZ-jQqi6Z8309Re8P9293T8Xzy-Pi7va5AMb4UFBQBoBVrWDEABGa8BZszfS8ppbrqmktq7RW-fegaVPqFqgGzrgWdVNzy07R753vOoaP0aRB9i6B6TrlTRiTbMqypFXZZLDegRBDStFYuY6uV3EjKZFTFnKbhZwWLYWQ2yzkpPu5HzC2vdFfVLvlZ-DXHlAJVGej8uDSfy4zRBD2FzsDlS8</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>MATSOUKAS, J. M</creator><creator>POLEVAYA, L</creator><creator>ANCANS, J</creator><creator>MAVROMOUSTAKOS, T</creator><creator>KOLOCOURIS, A</creator><creator>ROUMELIOTI, P</creator><creator>VLAHAKOS, D. V</creator><creator>YAMDAGNI, R</creator><creator>QIAO WU</creator><creator>MOORE, G. J</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2000</creationdate><title>The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II</title><author>MATSOUKAS, J. M ; POLEVAYA, L ; ANCANS, J ; MAVROMOUSTAKOS, T ; KOLOCOURIS, A ; ROUMELIOTI, P ; VLAHAKOS, D. V ; YAMDAGNI, R ; QIAO WU ; MOORE, G. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Angiotensin II - chemical synthesis</topic><topic>Angiotensin II - chemistry</topic><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Hormones. Endocrine system</topic><topic>Medical sciences</topic><topic>Nuclear Magnetic Resonance, Biomolecular</topic><topic>Peptides, Cyclic - chemistry</topic><topic>Peptides, Cyclic - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Conformation</topic><topic>Rats</topic><topic>Receptors, Angiotensin - chemistry</topic><topic>Receptors, Angiotensin - metabolism</topic><topic>Uterus - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MATSOUKAS, J. M</creatorcontrib><creatorcontrib>POLEVAYA, L</creatorcontrib><creatorcontrib>ANCANS, J</creatorcontrib><creatorcontrib>MAVROMOUSTAKOS, T</creatorcontrib><creatorcontrib>KOLOCOURIS, A</creatorcontrib><creatorcontrib>ROUMELIOTI, P</creatorcontrib><creatorcontrib>VLAHAKOS, D. V</creatorcontrib><creatorcontrib>YAMDAGNI, R</creatorcontrib><creatorcontrib>QIAO WU</creatorcontrib><creatorcontrib>MOORE, G. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MATSOUKAS, J. M</au><au>POLEVAYA, L</au><au>ANCANS, J</au><au>MAVROMOUSTAKOS, T</au><au>KOLOCOURIS, A</au><au>ROUMELIOTI, P</au><au>VLAHAKOS, D. V</au><au>YAMDAGNI, R</au><au>QIAO WU</au><au>MOORE, G. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2000</date><risdate>2000</risdate><volume>8</volume><issue>1</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>The novel amide linked Angiotensin II potent cyclic analogue, c-[Sar1,Lys3,Glu5] ANG II 19 has been designed and synthesized in an attempt to test the aromatic ring clustering and the charge relay bioactive conformation we have recently suggested for ANG II. This constrained cyclic analogue was synthesized by connecting the Lys3 amino and Glu5 carboxyl side chain groups, and it was found to be potent in the rat uterus assay and in anesthetized rabbits. The central part of the molecule is fixed covalently in the conformation predicted according to the backbone bend conformational model proposed for Angiotensin II. The obtained results using a combination of 2D NMR, 1D NOE spectroscopy and molecular modeling revealed a similar Tyr4-Ile5-His6 bend, a His6-Pro7 trans configuration and a side chain aromatic ring cluster of the key aminoacids Tyr4, His6, Phe8 for c-[Sar1,Lys3,Glu5] ANG II as it has been found for ANG II (Matsoukas, J. H.; Hondrelis, J.; Keramida, M.; Mavromoustakos, T.; Markriyannis, A.; Yamdagni, R.; Wu, Q.; Moore, G. J. J. Biol. Chem. 1994, 269, 5303). Previous study of the conformational properties of the Angiotensin II type I antagonist [Hser(gamma-OMe)8] ANG II (Matsoukas, J. M.; Agelis, G.; Wahhab, A.; Hondrelis, J.; Panagiotopoulos. D.; Yamdagni, R.; Wu, Q.; Mavromoustakos, T.; Maia, H.; Ganter, R.; Moore, G. J. J. Med. Chem. 1995, 38, 4660) using 1-D NOE spectroscopy coupled with the present study of the same type of lead antagonist Sarilesin revealed that the Tyr4-Ile5-His6 bend, a conformational property found in Angiotensin II is not present in type I antagonists. The obtained results provide an important conformational difference between Angiotensin II agonists and type I antagonists. It appears that our synthetic attempt to further support our proposed model was successful and points out that the charge relay system and aromatic ring cluster are essential stereoelectronic features for Angiotensin II to exert its biological activity.</abstract><cop>Oxford</cop><pub>Elsevier Science</pub><pmid>10968258</pmid><doi>10.1016/S0968-0896(99)00266-7</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2000, Vol.8 (1), p.1-10
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_72221427
source ScienceDirect Freedom Collection
subjects Angiotensin II - chemical synthesis
Angiotensin II - chemistry
Angiotensin II - pharmacology
Animals
Biological and medical sciences
Female
Hormones. Endocrine system
Medical sciences
Nuclear Magnetic Resonance, Biomolecular
Peptides, Cyclic - chemistry
Peptides, Cyclic - pharmacology
Pharmacology. Drug treatments
Protein Conformation
Rats
Receptors, Angiotensin - chemistry
Receptors, Angiotensin - metabolism
Uterus - drug effects
title The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A39%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20design%20and%20synthesis%20of%20a%20potent%20Angiotensin%20II%20cyclic%20analogue%20confirms%20the%20ring%20cluster%20receptor%20conformation%20of%20the%20hormone%20Angiotensin%20II&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=MATSOUKAS,%20J.%20M&rft.date=2000&rft.volume=8&rft.issue=1&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(99)00266-7&rft_dat=%3Cproquest_cross%3E72221427%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c336t-1caecc34b930ec09d06bcf53d851f6d47bf34dda896cd172dbc1dc636d95756f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72221427&rft_id=info:pmid/10968258&rfr_iscdi=true